Galderma
Five products, four of them for rosacea and pigment, and between them the most instructive set of labels in this register. One tells you to stop. One tells you it does not work on redness. One tells you not to use its antibiotic as an antibiotic. One publishes a table showing its own drug irritating two-thirds of the people who took it.
MODEL
New Drug Applications, manufactured products, retail pharmacy dispensing on a prescriber's script.
The brand verdict
Galderma is now the largest manufacturer in this register and the one whose labels teach the most. Tri-Luma is the approved triple combination that at least four telehealth compounders sell variations of. Soolantra has the strongest single-agent evidence base we have assessed. Oracea is the most purposeful piece of pharmaceutical engineering here. Mirvaso and Aklief are the two where the label's honesty works against the product, which is exactly why they are worth reading.
Read across the five and a consistent editorial habit appears: this company publishes the thing that costs it a sale. Tri-Luma's limitations of use state that it is not a maintenance treatment and that melasma usually recurs on stopping. Oracea's indication says in its first sentence that no meaningful effect was demonstrated for redness, and its limitations forbid using it for infection at all. Mirvaso's warnings record subjects whose erythema returned worse than baseline. Aklief prints an actively-assessed tolerability table showing erythema worse than baseline in 65% of subjects, beside a volunteered adverse-reaction rate of 7.5%.
The engineering is real too, and it is concentrated in the rosacea range. Oracea splits 40 mg of doxycycline into 30 mg immediate and 10 mg delayed release specifically to hold plasma concentrations below the antibacterial threshold, then proves the intent with an 18-month study of oral, skin, intestinal and vaginal flora. That is stewardship built into a formulation rather than asserted in a disclaimer, and nothing else in this register — manufactured or compounded — attempts it.
The recurring weakness is who the trials enrolled. Tri-Luma never studied Fitzpatrick V and VI and concedes excessive bleaching in darker skin cannot be excluded, for a condition that disproportionately affects pigmented skin. Soolantra's programme was 96% Caucasian, Mirvaso's 99%, Aklief's 87%. Every one of those figures is published and none of them is addressed. The second weakness is price: Aklief at around $693 for 45 g and Oracea at an average retail near $690 a month are both hard to defend on the molecules involved.
- Tri-Luma states all three concentrations in per cent and in milligrams per gram.
- Tri-Luma publishes both trials, including the one where success fell to 13%.
- Tri-Luma publishes all three two-drug comparator arms in the same vehicle.
- Tri-Luma carries the exogenous ochronosis warning and names the population most affected.
- Tri-Luma states that it is not a maintenance treatment and that melasma usually recurs.
- Soolantra publishes co-primary endpoints, both met in both trials.
- Soolantra publishes a long-term safety cohort with its size and duration.
- Oracea forbids the use of its own antibiotic for infection or prophylaxis.
- Oracea proves its sub-antimicrobial dosing with an 18-month bacterial flora study.
- Oracea warns that exceeding 40 mg increases the likelihood of bacterial resistance.
- Mirvaso records in its warnings that some subjects had erythema return worse than baseline.
- Aklief publishes an actively assessed tolerability table alongside the volunteered adverse reactions.
- Aklief publishes truncal efficacy as a formal endpoint — the only acne retinoid here that does.
- Aklief publishes sunburn incidence against vehicle, which most retinoid labels omit.
- All five state their trial demographics plainly, including the groups that were not represented.
The range
- R-352026-08-02
Tri-Luma
FLUOCINOLONE 0.01% / HYDROQUINONE 4% / TRETINOIN 0.05%The triple combination every compounded melasma formula is imitating, with the numbers the imitations do not publish: 38% and 13% completely cleared at eight weeks across two trials. The label calls it short-term, says melasma usually recurs, and refuses to be a maintenance product.
RECOMMENDED$294 PER 30 G TUBE
- R-402026-08-02
Soolantra
IVERMECTIN CREAM 1%Two trials, 1,371 subjects, a 65% reduction in inflammatory lesions and roughly two in five reaching clear or almost clear — and a safety database of 519 people who used it for a year. It is the best-evidenced single topical for papulopustular rosacea, and the reference the compounded versions are quietly diluting.
RECOMMENDED$100 PER TUBE
- R-482026-08-02
Oracea
DOXYCYCLINE 40 MG MODIFIED-RELEASEAn oral tetracycline deliberately dosed below the concentration that kills bacteria, with a label that forbids using it for infection and an 18-month study showing it leaves gut, skin, mouth and vaginal flora alone. This is the answer to every undosed antibiotic in this register.
RECOMMENDED$115 PER 30 CAPSULES
- R-502026-08-02
Aklief
TRIFAROTENE CREAM 0.005%The same trial reports irritation in 7.5% of users and in 65% of users, depending on whether anyone asked. Both numbers are on the label, and the gap between them is the most useful thing in this review.
CONDITIONAL$693 PER 45 G PUMP
- R-472026-08-02
Mirvaso
BRIMONIDINE TOPICAL GEL 0.33%The other approved treatment for rosacea redness, and on paper roughly twice as effective as the one at R-41. Its own label also records subjects whose erythema came back worse than it started. That sentence is the whole review.
CAUTION$168 PER TUBE
What repeats across the range
These are the findings a single review cannot make. Each one appears in more than one product, and each is drawn from the reviews above rather than from an impression of the brand.
- 01
The label says when to stop, and what it does not do
Tri-Luma: not indicated for maintenance, discontinue when control is achieved, melasma usually recurs. Oracea: indicated for inflammatory lesions only, with 'no meaningful effect was demonstrated for generalized erythema' in the indication and repeated after the results table. Two products, four sentences, all of them narrowing their own market.
- 02
Stewardship as a formulation decision
Oracea is dosed under the antibacterial threshold on purpose, forbids its own use for infection or prophylaxis, warns that exceeding 40 mg increases resistance risk, and backs the claim with an 18-month in vivo flora study. Set that against the telehealth services in this register dispensing topical and oral antibiotics on rolling supply with no stated duration.
- 03
Long-term safety is measured, not assumed
Soolantra reports 1,555 subjects beyond twelve weeks and 519 at approximately one year. Aklief reports a one-year open-label trial in 453 subjects with the discontinuation rate published at 2.9%. Oracea's controlled trials ran sixteen weeks, the longest in this register. These are chronic conditions and this is the only manufacturer here that has consistently studied them as such.
- 04
Comparator arms and failures are published in full
Tri-Luma's trials tested all three two-drug combinations in the identical vehicle — the pair without hydroquinone cleared nobody at all in trial 1 — and published the weaker trial at 13% beside the stronger at 38%. Oracea published two trials that differ twofold. Mirvaso published an adverse reaction table showing its own drug causing erythema and flushing more often than vehicle.
- 05
Aklief's two irritation figures are the most useful numbers here
Volunteered application site irritation, 7.5%. Actively assessed erythema worse than baseline, 65.2%. Same trials, same subjects, same twelve weeks. Publishing both makes the product look considerably worse and calibrates every other adverse-reaction percentage in this register: they are floors, not estimates.
- 06
Trial populations do not look like the patient population
Fitzpatrick V and VI excluded from Tri-Luma entirely; Soolantra 96% Caucasian; Mirvaso 99%; Aklief 87% Caucasian with 48% of subjects under eighteen. Melasma disproportionately affects pigmented skin and rosacea in skin of colour is under-diagnosed rather than absent. Every composition is disclosed; none of the implications is.
- 07
Two prices that the molecules do not support
Aklief at roughly $693 for a single 45 g pump intended to cover face and trunk, with no generic. Oracea at an average retail near $690 a month for a decades-old tetracycline, where the release profile rather than the molecule is the invention. The engineering in both cases is real; the retail arithmetic is not proportionate to it.
Disclosure scorecard
Not what is in the product — what the company publishes about it, and where. “Findable” means the concentration exists somewhere, such as a help-centre article, rather than on the page you buy from.
SCROLL THE TABLE SIDEWAYS